The General Services Administration has given the employees — who managed government workspaces — until the end of the week to accept or decline reinstatement, according to an internal memo obtained by The Associated Press. Those who accept must report to work on Oct. 6 after what amounts to a seven-month paid vacation.
"Ultimately, the outcome was the agency was left broken and understaffed," said Chad Becker, a former GSA real estate official. "They didn't have the people they needed to carry out basic functions."
Here's the latest:
"Early evidence that we've seen from rounds that were found near the suspected shooter contain messages that were anti-ICE in nature," said Joe Rothrock, special agent in charge of the Dallas field office.
SBA Pro-Life America and its Women Speak Out political action committee said Wednesday they plan to spend a total of $9 million backing anti-abortion candidates in next year's U.S. Senate races in Georgia and Michigan.
Both seats are now held by Democrats. The one in Michigan will be open in the election and the group wants to oust Democratic Sen. Joe Osoff in Georgia.
SBA spokesperson Kelsey Pritchard said a similar announcement on spending on a third battleground state will come next week.
The organization spent a total of about $13 million on independent political expenditures combined in 2022 and 2024 federal elections.
When President Trump's administration announced it would repurpose an old, generic drug as a new treatment for autism, it came as a surprise to many experts — including the physician who suggested the idea to the nation's top health officials.
Dr. Richard Frye told The Associated Press he'd been talking with federal regulators about developing his own customized version of the drug for children with autism, assuming more research would be required.
"So we were kinda surprised that they were just approving it right out of the gate without more studies or anything," said Frye, an Arizona-based child neurologist who has a book and online education business focused on the experimental treatment.
It's another example of the haphazard rollout of the Trump administration's Monday announcement on autism, which critics say has elevated an unproven drug that needs far more study before being approved as a credible treatment for the complex brain disease.